Tags : Cancer

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected […]Read More

Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel

Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will […]Read More

AbbVie Collaborates with Genmab to Develop and Commercialize Therapies for

Shots: Genmab to receive $750M as up front and is eligible to receive ~$3.15B as development, regulatory & commercial milestones for all programs along with royalties (22% – 26%) on sales for epcoritamab (ex- US & Japan). The collaboration includes development and commercialization of the three bispecific Ab therapeutic candidates The parties equally share pre-tax […]Read More

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline to

Shots: Shots: Boehringer Ingelheim acquires two preclinical programs from Northern Biologic to foster its cancer immunology portfolio in exchange Northern will receive upfront, milestones and other consideration payments. The acquisition will support Boehringer’s strategy to target ‘’cold tumors with synergistic combination approaches” The first program is an Ab inhibitor of Periostin, which contributes to cancer […]Read More

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific

Shots: The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis WuXi Biologics will be responsible for biologics discovery, process development, and manufacturing, whereas Aravive will be responsible for pre/ clinical development In 2018, Aravive and WuXi Biologics expanded their manufacturing collaboration for development and […]Read More

Pfizer’s Ruxience (biosimilar, rituximab) Receives EC’s Approval for Cancer Indications

Shots: The EC’s approval is based on the REFLECTIONS B3281006 study assessing efficacy, safety and immunogenicity, PK/PD of Ruxience that demonstrated the bio-similarity of Ruxience of its reference product, MabThera (rituximab) The approval follows the CHMP’s positive opinion received in Jan’2020. The therapy is made available to the adult patients with NHL, CLL, GPA and […]Read More

BMS Collaborates with Voluntis to Co-Develop Digital Therapies to Treat

Shots: The collaboration will deploy Voluntis’ Theraxium Oncology, a platform for digital therapies in oncology and will evaluate potential solutions to support the management of patients symptoms & remote monitoring by HCPs The focus of the collaboration is to develop digital therapies, providing patients access to a mobile app to support the treatment and track […]Read More

Pfizer’s Ruxience (biosimilar, rituximab) Receives CHMP’s Positive Opinion for Cancer

Shots: The EMA’s CHMP has adopted a positive opinion, recommending MAA for Ruxience, a biosimilar referencing MabThera The regulatory submission is based on REFLECTIONS B3281006 study assessing the efficacy, safety, immunogenicity, PK/PD of Ruxience demonstrating biosimilarity to the reference product in patients with CD20+, low tumor burden FL Ruxience is a mAb indicated for the […]Read More

Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat

Shots: • The companies enter into a collaboration to conduct a study assessing the combination of Innovent’s Tyvyt (sintilimab injection) and Sirnaomics’ RNAi drug candidate STP705 (cotsiranib) in advanced cancers including Hepatocellular Carcinomas (HCC) • The agreement will be the first example evaluating the combination of RNAi drug candidate, cotsiranib & immune checkpoint Ab, sintilimab […]Read More